Verona Pharma plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Verona Pharma plc
Venture capital and private equity firms pumped a combined $102m into seven Chinese biotechs in major deals announced during December.
After once again showing significant improvements in lung function and a 36% reduction in rate of exacerbations over 24 weeks, Verona is confident that its dual PDE3/4 inhibitor will change the treatment paradigm for COPD.
Verona Pharma’s Phase III ensifentrine, if approved, would be the first new dual-mechanism treatment class for COPD patients in decades. It could propel the UK-based biotech toward profitability, or into the arms of a larger partner.
The UK biotech is in a strong spot after extending its cash runway to prepare for the launch of ensifentrine, which analysts believe could become a pipeline-in-a-molecule for respiratory diseases.
- Medical Devices
- Drug Delivery
- Other Names / Subsidiaries
- Isis Resources plc
- Rhinopharma Limited
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.